German Rx-To-OTC Switch Committee To Consider Sildenafil Reclassification
Executive Summary
Rx-to-OTC switches of sildenafil and xylometazoline and ipratropium bromide combinations are on the cards for January's meeting of the German Expert Committee for Prescription.
You may also be interested in...
No OTC Sildenafil In Germany After Committee Rejects All Rx-To-OTC Switches
The German Expert Committee for Prescription has rejected the Rx-to-OTC reclassifications of sildenafil (50mg) for oral use and xylometazoline and ipratropium bromide for intranasal use.
Petros Includes Nitrate Patients In OTC ED Drug Self-Selection Studies
Firms also notes in its announcement that FDA typically requires actual use trials for switch NDAs in addition to label comprehension studies, which it has conducted, and self-selection studies.
Label Comprehension Results Point Petros Toward OTC Self-Selection Study For Stendra ED Drug
Petros considers switch NDA for Stendra (avanafil), approved for Rx sales in US since 2012 on an NDA by Metuchen. Early indicators showed positive outcomes in a 453-subject label comprehension study for the oral PDE5 inhibitor.